MA71234A - Formes à l'état solide de n-(2-(4-cyanothiazolidin-3-yl)-2-oxoéthyl)-6-morpholinoquinoléine-4-carboxamide - Google Patents

Formes à l'état solide de n-(2-(4-cyanothiazolidin-3-yl)-2-oxoéthyl)-6-morpholinoquinoléine-4-carboxamide

Info

Publication number
MA71234A
MA71234A MA71234A MA71234A MA71234A MA 71234 A MA71234 A MA 71234A MA 71234 A MA71234 A MA 71234A MA 71234 A MA71234 A MA 71234A MA 71234 A MA71234 A MA 71234A
Authority
MA
Morocco
Prior art keywords
cyanothiazolidin
morpholinoquinoline
oxoethyl
carboxamide
solid state
Prior art date
Application number
MA71234A
Other languages
English (en)
Inventor
Yvonne SAWYER
Anna ARDANÉ
Staffan Karlsson
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of MA71234A publication Critical patent/MA71234A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
MA71234A 2022-06-21 2023-06-20 Formes à l'état solide de n-(2-(4-cyanothiazolidin-3-yl)-2-oxoéthyl)-6-morpholinoquinoléine-4-carboxamide MA71234A (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263366696P 2022-06-21 2022-06-21
PCT/EP2023/066559 WO2023247487A1 (fr) 2022-06-21 2023-06-20 Formes à l'état solide de n-(2-(4-cyanothiazolidin-3-yl)-2-oxoéthyl)-6-morpholinoquinoléine-4-carboxamide
EP23734210.0A EP4543877A1 (fr) 2022-06-21 2023-06-20 Formes à l'état solide de n-(2-(4-cyanothiazolidin-3-yl)-2-oxoéthyl)-6-morpholinoquinoléine-4-carboxamide

Publications (1)

Publication Number Publication Date
MA71234A true MA71234A (fr) 2025-04-30

Family

ID=87047690

Family Applications (1)

Application Number Title Priority Date Filing Date
MA71234A MA71234A (fr) 2022-06-21 2023-06-20 Formes à l'état solide de n-(2-(4-cyanothiazolidin-3-yl)-2-oxoéthyl)-6-morpholinoquinoléine-4-carboxamide

Country Status (12)

Country Link
US (1) US20250368637A1 (fr)
EP (1) EP4543877A1 (fr)
JP (1) JP2025521304A (fr)
KR (1) KR20250027736A (fr)
CN (2) CN119585266A (fr)
AU (1) AU2023288645A1 (fr)
CA (1) CA3260370A1 (fr)
CL (1) CL2024003894A1 (fr)
IL (1) IL317722A (fr)
MA (1) MA71234A (fr)
MX (1) MX2024015644A (fr)
WO (1) WO2023247487A1 (fr)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1760076A1 (fr) * 2005-09-02 2007-03-07 Ferring B.V. Inhibiteur de FAP
CN113811529A (zh) * 2018-12-21 2021-12-17 普拉西斯生物技术有限责任公司 成纤维细胞激活蛋白抑制剂
CN116745291A (zh) * 2020-12-17 2023-09-12 阿斯利康(瑞典)有限公司 N-(2-(4-氰基噻唑烷-3-基)-2-氧代乙基)-喹啉-4-甲酰胺

Also Published As

Publication number Publication date
US20250368637A1 (en) 2025-12-04
CL2024003894A1 (es) 2025-02-07
AU2023288645A1 (en) 2025-02-13
KR20250027736A (ko) 2025-02-27
CA3260370A1 (fr) 2023-12-28
IL317722A (en) 2025-02-01
CN119585266A (zh) 2025-03-07
MX2024015644A (es) 2025-02-10
WO2023247487A1 (fr) 2023-12-28
CN120554349A (zh) 2025-08-29
JP2025521304A (ja) 2025-07-08
EP4543877A1 (fr) 2025-04-30

Similar Documents

Publication Publication Date Title
EP4161575A4 (fr) Formes cristallines d'agents de dégradation d'irak
EP4114702A4 (fr) Prédiction de comportement d'agents environnants
EP4178960A4 (fr) Sels et formes d'un inhibiteur de wee1
EP3923798A4 (fr) Détermination de paramètres de modèle à l'aide d'un modèle prédictif
EP4081828A4 (fr) Paramètres de mise à l'échelle pour v-pcc
EP3811994A4 (fr) Procédé d'assistance à l'expectoration pour ventilateur non invasif et ventilateur non invasif
MA55801A (fr) Formes solides d'un inhibiteur de glyt1
EP4162317A4 (fr) Lentille à projection asymétrique pour traiter l'astigmatisme
EP4241441A4 (fr) Mode d'appareil-photo d'enregistrement d'écran
EP4288078A4 (fr) Forme pharmaceutique prête à perfuser d'oxytocine
EP4259822A4 (fr) Compositions à tampon unique pour la détection d'acides nucléiques
MA71234A (fr) Formes à l'état solide de n-(2-(4-cyanothiazolidin-3-yl)-2-oxoéthyl)-6-morpholinoquinoléine-4-carboxamide
EP4263488A4 (fr) Formes solides d'un composé
EP4046130A4 (fr) Évaluation de la qualité d'une imprimante par attribution de scores de qualité à des images
EP3999023A4 (fr) Procédé d'incorporation d'acide oléanolique dans des compositions de soins bucco-dentaires et compositions de soins bucco-dentaires à base de celui-ci
EP4384525A4 (fr) Formes à l'état solide de rélugolix
MA53671A (fr) Formes cristallines d'un agoniste du récepteur farnésoïde x
EP4183859A4 (fr) Composition d'agent de nettoyage incorporé à l'amylase
EP3950282A4 (fr) Procédé de fabrication d'un corps moulé à la presse
EP4252391A4 (fr) Gestion précise d'un comportement de résolution d'acheminement
EP3987395A4 (fr) Dispositif électronique pour exécuter des instructions à l'aide de coeurs de processeur et de diverses versions d'architectures d'ensembles d'instructions
EP4255431A4 (fr) Formes solide de l'émétine
EP3941499A4 (fr) Composition pour l'inhibition compétitive d'agents pathogènes et le rétablissement de l'équilibre écologique microbien
EP2047859A4 (fr) Traitement d'une maladie ischémique à l'aide d'érythropoïétine
EP4200180A4 (fr) Suivi et prédiction du comportement d'un conducteur